National Comprehensive Cancer Network
Pharmacy Program:
Educational Events & Programs
Advances in the Use of Aromatase Inhibitors in the Treatment of Breast Cancer
A presentation from the NCCN 14th Annual Conference: Clinical Practice Guidelines & Quality Cancer Care™ held in Hollywood, Florida.
Presenter
George Somlo, MD
City of Hope Comprehensive Cancer Center
Los Angeles, CA
Disclosure of Affiliations and Significant Relationships
All faculty and activity planners participating in NCCN continuing education activities are expected to disclose any conflict(s) of interest related to the content of their presentation(s) as defined by the ACCME’s and ANCC’s Standards for Commercial Support. All faculty presentations have been reviewed for adherence to the ACCME’s Criterion 7: The provider develops activities/educational interventions independent of commercial interests (SCS 1, 2, and 6) by experts on the topics.
The speaker listed below has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:
George Somlo, MD
Consultant: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation
Grant/Research Support: AstraZeneca Pharmaceuticals LP; Pfizer Inc.
Product/Speakers’ Bureau: AstraZeneca Pharmaceuticals LP; Novartis Pharmaceuticals Corporation
Dr. Somlo has indicated that his presentation will include discussion of investigational or unlabeled uses of commercial products.
The conference planner listed below has disclosed that he has financial interests, arrangements, or affiliations with the manufacturer of any products or devices to be discussed in this activity or who may financially support the activity:
William T. McGivney, PhD*
Advisory Board: Bristol-Myers Squibb Company
Consultant: Mattson Jack DiVinci
Speaker: Center for Business Intelligence; The Confera Group; Health Industry Group Purchasing Association; Japan Comprehensive Cancer Network, Breast; Johnson & Johnson Services, Inc.; Whistler Associates
*All proceeds donated to charitable causes.
The Conference Planning Staff had no financial interests to disclose.
NCCN: Alana L. K. Brody, MBA; Lynn Cherrin, MS; Patricia A. Daulerio; Mark Geisler; Patricia J. Goldsmith; Kristina M. Gregory, RN, MSN, OCN; Kristin Kline Hasson; Lisa G. Kimbro, CPA, MBA; Jennifer L. McCann; Joan S. McClure, MS; Deirdre McKee, MPH; Diane McPherson; Liz Rieder; Shannon K. Ryan; Kelly C. Simpson; and Elizabeth L. Sweeney
Program Goal
The goal of this program is to provide participants with increased knowledge regarding the use of aromatase inhibitors in the treatment of breast cancer.
Educational Objectives
Following this activity, participants should be able to:
- Identify differences in the safety profiles of aromatase inhibitors and tamoxifen
- Counsel postmenopausal patients with hormone receptor-positive breast cancer about the risks and benefits of adjuvant aromatase inhibitors and of switching to an aromatase inhibitor after tamoxifen
- Provide patients with information on the risks and benefits of extended therapy with an aromatase inhibitor or tamoxifen
- Describe ongoing research on the use of adjuvant aromatase inhibitors with concurrent ovarian suppression in premenopausal patients with breast cancer
Intended Audience
This educational activity is designed to meet the needs of physicians, nurses, and other clinical professionals who manage patients with cancer.
Activity Instructions
Continuing education credit will be awarded to participants who listen to the presentation and complete the evaluation. Participants should review the learning objectives and faculty disclosure statements prior to listening to a presentation in its entirety. You must be connected to the Internet in order to review and complete the evaluation form. A statement of credit will be electronically generated once you complete the evaluation form. To receive credit, this activity must be completed no later than May 7, 2010. There is no fee for participating in this activity.
Accreditation Information
Physicians
The National Comprehensive Cancer Network (NCCN) is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
NCCN designates this educational activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
Nurses
This activity is approved for 0.9 contact hours. National Comprehensive Cancer Network is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.
Approval as a provider refers to recognition of educational activities only and does not imply ANCC Commission on Accreditation or PA Nurses approval or endorsement of any product.
Kristina M. Gregory, RN, MSN, OCN, is our nurse planner for this educational activity.
Release date: May 7, 2009
Expiration date: May 7, 2010
Commercial Support
Supported by educational grants from Novartis Oncology and Pfizer Inc.
E-mail
Print
Mark
|
|
|
|
|
|
|
||